التهاب الأوعية اللكوسيتوكلاستي مع الإصابة الجهازية للأعضاء عندما لم يُحقق الكبت المناعي الخطي الأول هدأة المرض

References

DOI: 10.1093/rheumatology/keac115

• Conversely, when a systemic vasculitis is the cause of LCV, higher doses of corticosteroids or immunosuppressive agents are required, according to the severity of organ involvement and the underlying associated disease.
• Stronger and more toxic agents, such as cyclophosphamide may be effective, but should be limited to severe systemic vasculitides with organ-threatening involvement.
• Finally, in the current era of biologic therapies, targeting anti-CD20 with rituximab has now an established role in the treatment of ANCA-associated vasculitides, as well as in cryoglobulinemic vasculitis and HUV.
• Rituximab appears promising also for HSP, when severe systemic or renal involvement favors an immunosuppressive or a corticosteroids sparing therapy.
• When polyneuropathy or kidney involvement are present, immunosuppressive treatment or plasma-exchange strategies are usually required.
• In general, the treatment depends on the diagnosis and aims to induce and maintain disease remission.